Alzheimer's disease Archimedes condition-event simulator: Development and validation.

about

Alzheimer's disease Archimedes condition-event simulator: Development and validation.

Item

http://www.wikidata.org/entity/Q52568119

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Alzheimer's disease Archimedes condition-event simulator: Development and validation.

@en

Alzheimer's disease Archimedes condition-event simulator: Development and validation.

@nl

type

Item

label

Alzheimer's disease Archimedes condition-event simulator: Development and validation.

@en

Alzheimer's disease Archimedes condition-event simulator: Development and validation.

@nl

prefLabel

Alzheimer's disease Archimedes condition-event simulator: Development and validation.

@en

Alzheimer's disease Archimedes condition-event simulator: Development and validation.

@nl

P1476

Alzheimer's disease Archimedes condition-event simulator: Development and validation.

@en

P2093

Ali Tafazzoli

http://www.w3.org/2001/XMLSchema#string

Anuraag R Kansal

http://www.w3.org/2001/XMLSchema#string

K Jack Ishak

http://www.w3.org/2001/XMLSchema#string

Stanmira Krotneva

http://www.w3.org/2001/XMLSchema#string

P2860

Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the national Alzheimer's coordinating center database.

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.

The natural history of cognitive decline in Alzheimer's disease.

Preference-Based EQ-5D index scores for chronic conditions in the United States

Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis.

Decision analytic models for Alzheimer's disease: state of the art and future directions.

Rates of hippocampal atrophy correlate with change in clinical status in aging and AD.

Biracial population study of mortality in mild cognitive impairment and Alzheimer disease.

A new algorithm for predicting time to disease endpoints in Alzheimer's disease patients.

P304

76-88

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.TRCI.2018.01.001

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-02-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29687076

http://www.w3.org/2001/XMLSchema#string

P932

5910516

http://www.w3.org/2001/XMLSchema#string